Charles Swanton | |
---|---|
Born | Robert Charles Swanton 1972 (age 50–51) [1] |
Education | St Paul's School, London |
Alma mater | University College London (MD, PhD) |
Awards | Ellison–Cliffe Lecture (2017) EMBO Member (2017) |
Scientific career | |
Fields | Cancer evolution [2] |
Institutions | Francis Crick Institute University College London |
Thesis | Viral cyclin disruption of mammalian cell cycle control mechanisms (1998) |
Doctoral advisor | Nic Jones |
Website | www |
(Robert) Charles Swanton FRS FMedSci FRCP is British physician scientist specialising in oncology and cancer research. Swanton is a senior group leader at London's Francis Crick Institute, [3] Royal Society Napier Professor in Cancer [4] and thoracic medical oncologist at University College London [5] and University College London Hospitals, [6] [7] co-director of the Cancer Research UK (CRUK) Lung Cancer Centre of Excellence, and Chief Clinician of Cancer Research UK. [8] [9]
Swanton completed was educated at St Paul's School, London [1] and completed his PhD in 1999 [10] at what was then the Imperial Cancer Research Fund Laboratories (now the Francis Crick Institute) and his Cancer Research UK clinician scientist/medical oncology training in 2008. [7]
Swanton combines his laboratory research with clinical duties as co-director of the CRUK Lung Cancer Centre, focussed on how tumours evolve over space and time. [7] He has helped to define the branched evolutionary histories of solid tumours, processes that drive cancer cell-to-cell variation in the form of new cancer mutations or chromosomal instabilities, and the impact of such cancer diversity on effective immune surveillance and clinical outcome. [2] [7] [11] [12]
Swanton is a co-founder of Achilles Therapeutics [13] with Sergio Quezada, Karl Peggs and Mark Lowdell. Achilles Therapeutics is a UCL/CRUK and Francis Crick Institute [14] biotechnology company funded by Syncona [15] that develops adoptive T cell therapies targeting clonal/truncal neo-antigens present in every tumour cell to limit drug resistance and tumour evolution.[ citation needed ]
Swanton is the son of Robert Howard Swanton (MD, FRCP) a consultant cardiologist at UCL. [23]
Cancer Research UK (CRUK) is the world's largest independent cancer research organisation. It is registered as a charity in the United Kingdom and Isle of Man, and was formed on 4 February 2002 by the merger of The Cancer Research Campaign and the Imperial Cancer Research Fund. Cancer Research UK conducts research using both its own staff and grant-funded researchers. It also provides information about cancer and runs campaigns aimed at raising awareness and influencing public policy.
Karen Heather Vousden, CBE, FRS, FRSE, FMedSci is a British medical researcher. She is known for her work on the tumour suppressor protein, p53, and in particular her discovery of the important regulatory role of Mdm2, an attractive target for anti-cancer agents. From 2003 to 2016, she was the director of the Cancer Research UK Beatson Institute in Glasgow, UK, moving back to London in 2016 to take up the role of Chief Scientist at CRUK and Group Leader at the Francis Crick Institute.
John Gordon McVie was an international authority on the treatment and research of cancer. He wrote over 350 peer-reviewed articles, editorials and books. McVie was born in Glasgow, Scotland and died of non-Hodgkin lymphona and COVID-19 in Bristol, England.
Tomas Robert Lindahl FRS FMedSci is a Swedish-British scientist specialising in cancer research. In 2015, he was awarded the Nobel Prize in Chemistry jointly with American chemist Paul L. Modrich and Turkish chemist Aziz Sancar for mechanistic studies of DNA repair.
Christopher John Marshall FRS FMedSci was a British scientist who worked as director of the Division for Cancer Biology at the Institute of Cancer Research. Marshall was distinguished for research in the field of tumour cell signalling. His track record includes the discovery of the N-Ras oncogene , the identification of farnesylation of Ras proteins, and the discovery that Ras signals through the MAPK/ERK pathway. These findings have led to therapeutic development of inhibitors of Ras farnesylation, MEK and B-Raf.
Frances Rosemary Balkwill is an English scientist, Professor of Cancer Biology at Queen Mary University of London, and author of children's books about scientific topics.
Hani Gabra PhD FRCPE FRCP is a British oncologist and Professor Emeritus in Medical Oncology at Imperial College London.
Sir Melvyn Francis Greaves FMedSci, FRS is a British cancer biologist, and Professor of Cell Biology at the Institute of Cancer Research (ICR) in London. He is noted for his research into childhood leukaemia and the roles of evolution in cancer, including important discoveries in the genetics and molecular biology underpinning leukaemia.
Tony Kouzarides, FMedSci, FRS is a senior group leader Gurdon Institute, a founding non-executive director of Abcam and a Professor of Cancer Biology at the University of Cambridge.
Sir James Cuthbert Smith is Director of Science at the Wellcome Trust, Senior Group Leader at the Francis Crick Institute and President of the Council at Zoological Society of London.
Anne Jacqueline Ridley is professor of Cell Biology and Head of School for Cellular and Molecular Medicine at the University of Bristol. She was previously a professor at King's College London.
James Briscoe is a senior group leader at the Francis Crick Institute in London and editor-in-chief of the journal Development.
Caroline Dive is a British cancer research scientist. Dive is Professor of Cancer Pharmacology at the University of Manchester, Deputy Director of the Cancer Research UK (CRUK) Manchester Institute, Director of the CRUK Manchester Institute Cancer Biomarker Centre and co-director of the CRUK Lung Cancer Centre of Excellence. She is the current President of The European Association for Cancer Research (EACR).
Richard Malcolm Marais is Director of the Cancer Research UK (CRUK) Manchester Institute and Professor of Molecular Oncology at the University of Manchester.
Sir Richard Henry Treisman is a British scientist specialising in the molecular biology of cancer. Treisman is a director of research at the Francis Crick Institute in London.
Gregory James Hannon is a professor of molecular cancer biology and director of the Cancer Research UK Cambridge Institute at the University of Cambridge. He is a Fellow of Trinity College, Cambridge while also serving as a director of cancer genomics at the New York Genome Center and an adjunct professor at Cold Spring Harbor Laboratory.
Elizabeth Ruth Plummer is a Professor of Experimental Cancer Medicine at Newcastle University and an oncologist specialising in treating patients with melanoma. Based in Newcastle, she directs the Sir Bobby Robson Cancer Trials Research Centre, set up by the Sir Bobby Robson Foundation to run early-stage clinical trials.v Plummer and the Newcastle team won a 2010 Translational Cancer Research Prize from Cancer Research UK for work using rucaparib to treat ovarian cancer. Plummer was elected as a fellow of the UK's Academy of Medical Sciences in 2018.
Professor Richard James Gilbertson is a paediatric oncology clinician scientist and a Senior Group Leader at the Cancer Research UK Cambridge Institute, University of Cambridge. He is the Li Ka Shing Chair of Oncology, and Director of the CRUK Cambridge Major Centre and the Children's Brain Tumour Centre of Excellence.
Caetano Maria Pacheco Pais dos Reis e Sousa is a senior group leader at the Francis Crick Institute and a professor of Immunology at Imperial College London.
Axel Behrens is a German-British molecular biologist and an expert in cancer stem cell biology. He is the Scientific Director of the Cancer Research UK Convergence Science Centre in London, a senior group leader at the Institute of Cancer Research and a professor at Imperial College London.
"All text published under the heading 'Biography' on Fellow profile pages is available under Creative Commons Attribution 4.0 International License." -- "Terms, conditions and policies | Royal Society". Archived from the original on 11 November 2016. Retrieved 27 June 2018.{{cite web}}
: CS1 maint: bot: original URL status unknown (link)
This article incorporates text available under the CC BY 4.0 license.